Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
Fish and Richardson
Johnson and Johnson
Harvard Business School

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206352

« Back to Dashboard

NDA 206352 describes REYATAZ, which is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from six suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the REYATAZ profile page.

The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-three drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.

Summary for 206352

Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 206352

Suppliers and Packaging for NDA: 206352

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REYATAZ atazanavir sulfate POWDER;ORAL 206352 NDA E.R. Squibb & Sons, L.L.C. 0003-3638 0003-3638-10 30 PACKET in 1 CARTON (0003-3638-10) > 1 POWDER in 1 PACKET

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 50MG BASE/PACKET
Approval Date:Jun 2, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 24, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Jun 2, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Dec 2, 2017
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: